CriticalTriptan, selective 5HT1B/1D receptor agonist×Reversible MAO-A inhibitor (RIMA)
Updated · Methodology
Mechanism
Moclobemide reversibly inhibits monoamine oxidase (MAO), mainly type A, and slows the breakdown of serotonin, noradrenaline and dopamine (moclobemide summary of product characteristics, SmPC, section 5.1). Frovatriptan is a selective agonist of the serotonin 5-HT1B and 5-HT1D receptors (frovatriptan SmPC, section 5.1). The moclobemide SmPC contraindicates triptans because MAO and cytochrome P450 (CYP) enzymes metabolise them and their plasma concentrations rise with moclobemide (section 4.5). The frovatriptan documents do not support this for frovatriptan. MAO does not metabolise it, CYP1A2 is the main enzyme in its metabolism, and moclobemide 150 mg twice daily for 8 days did not change frovatriptan pharmacokinetics (Spanish frovatriptan SmPC, sections 4.5 and 5.2; frovatriptan label, US Food and Drug Administration, FDA, section 12.3). The risk of the pair comes from the effects of both drugs on serotonin and blood vessels: the Spanish frovatriptan SmPC does not rule out serotonin syndrome or a rise in blood pressure with MAO inhibitors (section 4.5).
Symptoms
The documents do not describe how this particular combination presents, because the moclobemide summary of product characteristics (SmPC) contraindicates it in advance (sections 4.3 and 4.5). The main danger is serotonin syndrome: mental status changes (agitation, hallucinations, coma), autonomic instability (fast heart rate, labile blood pressure, high temperature), neuromuscular changes (hyperreflexia, poor coordination), nausea, vomiting and diarrhoea. It usually starts within minutes to hours of a new or higher dose of a serotonergic drug (frovatriptan label, US Food and Drug Administration, FDA, section 5.7). The Spanish frovatriptan SmPC also names a risk of raised blood pressure with monoamine oxidase inhibitors (section 4.5). The FDA label reports rare cases of marked rises in blood pressure in people taking 5-HT1 agonists, up to hypertensive crisis with acute organ damage (section 5.8).
Management
The combination is contraindicated. The moclobemide summary of product characteristics (SmPC) lists triptans among contraindicated drugs and names frovatriptan explicitly (moclobemide SmPC, sections 4.3 and 4.5). The frovatriptan documents are softer. The Spanish SmPC places monoamine oxidase (MAO) inhibitors among combinations that are not recommended (section 4.5; the frovatriptan authorisation in Spain was revoked in 2024). The US Food and Drug Administration (FDA) label does not list MAO inhibitors among its contraindications (section 4). The strictest document prevails, so do not prescribe frovatriptan to people taking moclobemide. No document gives an interval between stopping one drug and starting the other. If the two drugs have nevertheless been taken together and serotonin syndrome is suspected, stop frovatriptan (FDA frovatriptan label, section 5.7). The moclobemide SmPC advises considering a lower moclobemide dose or stopping it, depending on how severe the symptoms are (section 4.4). Monitor blood pressure in people taking frovatriptan (FDA frovatriptan label, section 5.8).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Frovatriptán (nº registro 65009), sección 4.5 (2023)– AEMPS, CIMA, nº registro 65009 (Forvey 2,5 mg, Menarini; autorización revocada 05/2024), revisión 02/2023, sección 4.5
- FDA: Frovatriptan succinate tablets, Leading Pharma (frovatriptan) prescribing information (2026)– FDA, DailyMed setid d303af88-e0c1-4fb2-ba8e-83b7e6d163cd, revisión 06/2026 (versión 2), secciones 4, 5.1, 5.2, 5.3, 5.5, 5.6, 5.7, 5.8, 7.1, 7.3, 10 y 12.3
- AEMPS: Ficha técnica: Moclobemida, Manerix 300 mg (nº registro 60824) (2025)– AEMPS, CIMA, nº registro 60824 (Manerix 300 mg comprimidos recubiertos con película), revisión 06/2025, secciones 4.3, 4.5, 5.1 y 5.2